# Methylphenidate - Most widely used ADHD medication globally
# Approved in US, China, EU, Japan, and many other countries

id: "methylphenidate"

brandNames:
  US: ["Concerta", "Ritalin", "Ritalin LA", "Metadate CD", "Metadate ER", "Methylin", "Quillivant XR", "Quillichew ER", "Jornay PM", "Aptensio XR", "Cotempla XR-ODT", "Daytrana"]
  CN: ["专注达 (Concerta)"]
  EU: ["Concerta", "Ritalin", "Equasym", "Medikinet", "Rubifen", "Tuzulby"]
  JP: ["コンサータ (Concerta)", "リタリン (Ritalin)"]
  UK: ["Concerta XL", "Ritalin", "Equasym XL", "Medikinet XL", "Xaggitin XL"]
  AU: ["Concerta", "Ritalin", "Ritalin LA"]
  CA: ["Concerta", "Ritalin", "Biphentin"]

genericName: "methylphenidate hydrochloride"

manufacturers:
  - name: "Janssen (Johnson & Johnson)"
    region: "US"
    product: "Concerta"
  - name: "Novartis"
    region: "US"
    product: "Ritalin"
  - name: "西安杨森 (Janssen China)"
    region: "CN"
    product: "专注达"
  - name: "Shionogi"
    region: "JP"
    product: "コンサータ"

# Classification
drugClass: "stimulant"
category: "methylphenidate"
controlledSubstance: true
schedule:
  US: "Schedule II"
  CN: "第一类精神药品 (Class I Psychotropic)"
  EU: "Varies by country"
  JP: "第一種向精神薬"
  UK: "Class B, Schedule 2"

# Mechanism
activeIngredient: "methylphenidate hydrochloride"
mechanismOfAction: "Blocks reuptake of dopamine and norepinephrine, increasing their concentration in the synaptic cleft. Primarily affects the prefrontal cortex to improve attention and executive function."
neurotransmittersAffected:
  - dopamine
  - norepinephrine

# Dosage & Forms
forms:
  - type: "tablet"
    releaseType: "immediate"
    brandName: "Ritalin"
    strengths: ["5mg", "10mg", "20mg"]
    durationHours: 3-4
    notes: "Usually taken 2-3 times daily"

  - type: "tablet"
    releaseType: "extended"
    brandName: "Concerta"
    strengths: ["18mg", "27mg", "36mg", "54mg"]
    durationHours: 10-12
    notes: "OROS technology, once daily dosing"

  - type: "capsule"
    releaseType: "extended"
    brandName: "Ritalin LA"
    strengths: ["10mg", "20mg", "30mg", "40mg"]
    durationHours: 8-10
    notes: "Can be opened and sprinkled on food"

  - type: "capsule"
    releaseType: "extended"
    brandName: "Metadate CD"
    strengths: ["10mg", "20mg", "30mg", "40mg", "50mg", "60mg"]
    durationHours: 8
    notes: "30% immediate release, 70% extended release"

  - type: "patch"
    releaseType: "extended"
    brandName: "Daytrana"
    strengths: ["10mg/9hr", "15mg/9hr", "20mg/9hr", "30mg/9hr"]
    durationHours: 9-12
    notes: "Transdermal patch, wear for 9 hours"

  - type: "liquid"
    releaseType: "extended"
    brandName: "Quillivant XR"
    strengths: ["25mg/5mL"]
    durationHours: 12
    notes: "Liquid suspension for those who can't swallow pills"

  - type: "capsule"
    releaseType: "extended"
    brandName: "Jornay PM"
    strengths: ["20mg", "40mg", "60mg", "80mg", "100mg"]
    durationHours: 12
    notes: "Evening dosing, works by morning"

  - type: "chewable"
    releaseType: "extended"
    brandName: "Quillichew ER"
    strengths: ["20mg", "30mg", "40mg"]
    durationHours: 8
    notes: "Cherry-flavored chewable tablet"

  - type: "ODT"
    releaseType: "extended"
    brandName: "Cotempla XR-ODT"
    strengths: ["8.6mg", "17.3mg", "25.9mg"]
    durationHours: 12
    notes: "Orally disintegrating tablet"

# Efficacy
onsetMinutes: 30-60
peakEffectHours: 2
durationHours: 4-12  # depends on formulation

# Side Effects
sideEffects:
  common:
    - name: "decreased appetite"
      frequency: "25-40%"
    - name: "insomnia"
      frequency: "20-30%"
    - name: "headache"
      frequency: "15-25%"
    - name: "stomach ache"
      frequency: "10-20%"
    - name: "irritability"
      frequency: "10-15%"
    - name: "weight loss"
      frequency: "10-15%"

  uncommon:
    - name: "increased heart rate"
      frequency: "5-10%"
    - name: "increased blood pressure"
      frequency: "5-10%"
    - name: "anxiety"
      frequency: "5-8%"
    - name: "dizziness"
      frequency: "5%"
    - name: "nausea"
      frequency: "5%"

  serious:
    - name: "cardiovascular events"
      notes: "Rare; increased risk in those with pre-existing heart conditions"
    - name: "psychiatric symptoms"
      notes: "May exacerbate psychosis or mania in susceptible individuals"
    - name: "growth suppression"
      notes: "May slow growth in children; effect usually temporary"
    - name: "priapism"
      notes: "Rare but serious; requires immediate medical attention"
    - name: "peripheral vasculopathy"
      notes: "Raynaud's phenomenon reported"

# Safety
contraindications:
  - "Hypersensitivity to methylphenidate"
  - "MAO inhibitor use within 14 days"
  - "Glaucoma"
  - "Severe anxiety, tension, or agitation"
  - "Motor tics or family history of Tourette's syndrome"
  - "Pheochromocytoma"

drugInteractions:
  - drug: "MAO inhibitors"
    severity: "major"
    effect: "Hypertensive crisis risk"
  - drug: "Antihypertensives"
    severity: "moderate"
    effect: "May reduce effectiveness of blood pressure medications"
  - drug: "Anticoagulants (warfarin)"
    severity: "moderate"
    effect: "May increase anticoagulant effect"
  - drug: "Seizure medications"
    severity: "moderate"
    effect: "May affect seizure threshold"
  - drug: "SSRIs"
    severity: "minor"
    effect: "May increase serotonergic effects"

blackBoxWarnings:
  - "High potential for abuse and dependence"
  - "Sudden death reported in patients with pre-existing structural cardiac abnormalities"

pregnancyCategory: "C"
foodInteractions: "Avoid high-fat meals with some formulations (may affect absorption); acidic foods/drinks may reduce absorption"

# Practical Information
typicalDosing:
  children:
    startingDose: "5mg twice daily (IR) or 18mg once daily (ER)"
    maxDose: "60mg/day (or 2mg/kg/day)"
    notes: "Start low, titrate weekly"
  adults:
    startingDose: "10mg twice daily (IR) or 18-36mg once daily (ER)"
    maxDose: "72mg/day (Concerta) or 60mg/day (other ER)"
    notes: "May need higher doses than children"

costEstimate:
  US:
    brand: "$300-500/month"
    generic: "$30-80/month"
  CN:
    brand: "¥300-600/month (专注达)"
    generic: "Limited availability"

storageRequirements: "Room temperature (20-25°C), protect from moisture and light"

# Approval & Availability
approvals:
  - region: "US"
    agency: "FDA"
    year: 1955
    approvedAges: "6 years and older"
    indications:
      - "ADHD"
      - "Narcolepsy"
    available: true
    notes: "Original Ritalin; Concerta approved 2000"

  - region: "CN"
    agency: "NMPA"
    year: 2005
    approvedAges: "6 years and older"
    indications:
      - "ADHD"
    available: true
    notes: "Only extended-release (专注达) widely available; supply shortages reported 2024-2025"

  - region: "EU"
    agency: "EMA"
    year: 1954
    approvedAges: "6-17 years (varies by country for adults)"
    indications:
      - "ADHD"
    available: true
    notes: "Adult approval varies by EU member state; Tuzulby approved Feb 2025"

  - region: "JP"
    agency: "PMDA"
    year: 2007
    approvedAges: "6 years and older"
    indications:
      - "ADHD"
    available: true
    notes: "Requires registration in ADHD Proper Distribution Management System since 2019"

  - region: "UK"
    agency: "MHRA"
    year: 1955
    approvedAges: "6 years and older"
    indications:
      - "ADHD"
    available: true
    notes: ""

  - region: "AU"
    agency: "TGA"
    year: 1966
    approvedAges: "6 years and older"
    indications:
      - "ADHD"
      - "Narcolepsy"
    available: true
    notes: ""

  - region: "CA"
    agency: "Health Canada"
    year: 1979
    approvedAges: "6 years and older"
    indications:
      - "ADHD"
      - "Narcolepsy"
    available: true
    notes: ""

# Special Considerations
specialConsiderations:
  cardiacRisk: "Cardiovascular evaluation recommended before starting; caution in patients with heart conditions"
  abuseRisk: "Schedule II controlled substance; high abuse potential, especially IR formulations"
  withdrawalNotes: "No significant physical withdrawal; may experience fatigue and depression when stopping"
  monitoringRequired: "Height, weight, blood pressure, heart rate; periodic cardiovascular assessment"

# Metadata
lastUpdated: 2025-12-02
sources:
  - "https://chadd.org/about-adhd/adhd-medications-approved-by-the-us-fda/"
  - "https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate"
  - "https://zhuanlan.zhihu.com/p/699401044"
  - "https://h-navi.jp/column/article/35028853"

notes: "Most widely prescribed ADHD medication globally. Multiple formulations available to suit different needs. China experiencing supply shortages as of 2024-2025."
